A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

NCT02066909 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: 0.15 mg PF-06649751
DRUG: 0.5 mg PF-06649751
DRUG: 0.5 mg PF-06649751
DRUG: 1.5 mg PF-06649751
DRUG: 1.5 mg PF-06649751 21 Days
DRUG: 3.0 mg PF-06649751
DRUG: 5.0 mg PF-06649751
DRUG: 8.0 mg PF-06649751
DRUG: 1.5 mg PF-06649751 in healthy Japanese subjects

Sponsor

Pfizer